Kordata Launches To Advance Neurotech-Powered Clinical Trials

Kordata Dynamics has come out of stealth mode to seize a $26 billion market opportunity aimed at resolving the backlog in clinical trials for central nervous system (CNS) therapeutics. The company plans to achieve this through innovative patient-centered neurotechnology and a comprehensive enterprise B2B strategy.

BIOS Health has provided the foundational intellectual property and business framework for Kordata, maintaining a majority stake in the new venture. Both companies were founded by Emil Hewage, who will serve as Kordata’s CEO, while Dawn McCollough, who has a history with Biogen and Novartis managing 15,000 clinical trials, steps in as president.

I had a conversation with Hewage about Kordata’s innovative approach to integrating neural data into the life sciences sector.

• Business Model: Kordata collaborates with major health systems and academic medical centers to establish new trial locations for pharmaceutical and life sciences companies. The company will generate revenue through volume-based licensing fees for their tools and additional fees from new clinical trial sponsorships at partner sites.
• Target Market: Kordata is focusing on life sciences companies, as Hewage mentioned, particularly those with precise products, tight dosing requirements, or specific inclusion criteria for novel trials. The initial emphasis will be on drug discovery and device optimization for Alzheimer’s, Parkinson’s, and Epilepsy, with potential expansion into drug-resistant chronic diseases in cardiology and immunology.
• Tech Stack as a Service: According to Hewage, their health system partners have “capacity, but not capability” to manage large trials. Despite having large patient volumes and clinical workforces, traditional healthcare systems lack the modern neuroimaging, recording, and transmission technologies necessary to securely deliver novel data to trial sites, while complying with institutional review board (IRB) and clinical research organization (CRO) standards.
• Decoding Neural Data: The BIOS platform, NeuroTune, is the backbone of Kordata’s operations, providing real-time dosing adjustments based on individual treatment responses. Hewage explained, “The nervous system reacts faster than any other part of the body to medical interventions, often within milliseconds, allowing us to observe organ and brain responses.” NeuroTune facilitates easy access to new data sources from implanted systems or wearable devices, enabling partner sites to assess patient reactions to various treatments.

During a private launch event recently, Hewage noted that attendees included leaders from the Royal College of Surgeons, NVIDIA, various startups, and municipal authorities, along with Kordata’s investors: Kern Venture Group, MAVRK Celestia Fund, and Digital Neural Infrastructure Holdings.

Operating from Bakersfield, CA, Kordata benefits from a well-established network of public payers and clinical sites, providing a rich recruitment environment for life sciences collaborations, given the diverse industries and socioeconomic backgrounds of the local population.

The potential for neurotechnology to revolutionize drug discovery is well recognized, although it has been hindered by the inertia of outdated systems and mindsets. Kordata’s launch coincides with a transformative period where artificial intelligence is reshaping market approaches.

The indications are increasingly clear that biotech represents neurotech’s next major frontier. This is evidenced by the FDA’s new real-time clinical trials initiative, the rise of neurotech leaders in CNS, increased efforts to commercialize psychedelics, significant investment in brain implants, and the emergence of comprehensive neurotech-healthcare collaborations, marking a new era for clinical research.